Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:1 September 2023

DeLLphi-304: This study is testing whether immunotherapy is more effective than the current standard of care treatment for people with relapsed small cell lung cancer who have platinum-based first line chemotherapyA Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive immunotherapy (called tarlatamab) as an intravenous (IV) infusion. In the Active Comparator Arm, participants will receive treatment with their local standard of care treatment, either lurbinectedin, topotecan or amrubicin.

Treatment Type

Systemic therapy (chemotherapy, hormone therapy or immunotherapy)

Age

People 18+

Phase

III

Trial Acronym

DeLLphi-304

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT05740566
20210004

Commercial Sponsor

AMGEN

Scientific Title

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have been diagnosed with a prior or secondary type of cancer.
You have had certain treatments, surgical procedures or drugs.
You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

You have had a certain type of treatment or surgical procedure.
You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You have had treatment, but your cancer has come back.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy